Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
A Phase 1 Study of Gemcitabine, Nab-Paclitaxel, and Bosentan in Patients With Unresectable Pancreatic Cancer
City of Hope Medical Center
21 participants
Sep 1, 2021
INTERVENTIONAL
Conditions
Summary
This phase I trial studies the side effects and best dose of bosentan and how well it works when given together with gemcitabine and nab-paclitaxel for the treatment of pancreatic cancer that cannot be removed by surgery (unresectable). Bosentan may block the hormone endothelin and prevent the growth and spread of pancreatic cancer. Drugs used in chemotherapy, such as gemcitabine and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving bosentan with chemotherapy (gemcitabine and nab-paclitaxel) may work better in treating patients with pancreatic cancer compared to chemotherapy alone.
Eligibility
Inclusion Criteria10
- Adult patients with unresectable pancreatic carcinoma
- Patients must be a candidate to receive one of the following chemotherapy combinations as determined by the treating physician:
- Arm A2: gemcitabine plus nab-paclitaxel given every 2 weeks (arm A1 is closed per this amendment)
- Arm B: mFOLFIRINOX given every 2 weeks
- Willingness to permit study team to obtain and use archival tissue, if already existing, or, be willing to undergo a fresh tumor biopsy if clinically possible (exceptions may be provided by study PI if medically unsafe to perform biopsy).
- Weight ≥ 40 kg
- ANC ≥ 1500/mm3; platelets ≥ 100,000/mm3
- AST, ALT ≤ 1.5 x ULN. Patients with liver metastases ≤ 3 x ULN
- Total serum bilirubin ≤ 1.5 x ULN
- Creatinine clearence ≥ 60 mL/min
Exclusion Criteria8
- Current or planned use of Warfarin, Cyclosporine A, Rifampicin, Glyburide (other diabetic medications are allowed)
- Current or planned use of agents contraindicated for use with strong CYP3A4 inducers
- Strong inhibitors or inducers of CYP2C9
- Strong inhibitors or inducers of CYP3A
- Agent or agents that moderately inhibit both CYP2C9 and CYP3A (via a single concomitant agent, or co-administration of concomitant agents)
- No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for five years.
- Current or history of ≥ Grade 2 peripheral neuropathy
- Known allergy to eggs or any of the components within the study agents and/or their excipients.
Interventions
Given PO
Given IV
Given IV
Ancillary studies
Ancillary studies
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04158635